Oman End-Stage Renal Disease Market Size, Share & Forecast, By Treatment Modality, Care Setting & Payer Type, 2025-2032

The Oman End-Stage Renal Disease Market is worth USD 52 million in 2025 on a provider service-revenue basis. The estimate covers renal replacement therapy delivered to the prevalent ESKD population, principally maintenance hemodialysis, alongside peritoneal dialysis, home-care pathways and kidney transplant-related services. Approximately 3,026 prevalent dialysis patients and nearly 393,985 annual hemodialysis sessions underpin the 2025 base. Public providers continue to deliver most treatment volume, while private hospitals represent a smaller but economically higher-value insured and self-pay component.

The market is forecast to reach approximately USD 103 million by 2032, representing a 10.3% CAGR during 2025-2032. Value growth is projected to exceed dialysis-session volume growth as the market absorbs healthcare input inflation, greater complexity of renal management and a gradual increase in insured private treatment. Hemodialysis sessions are modeled to reach approximately 632,655 by 2032, while prevalent dialysis patients approach 4,859. Capacity investment therefore remains necessary even if home dialysis and transplantation expand during the period.

The principal profit-pool shift is toward the insured private-care layer, although government-funded treatment will remain dominant in patient volume. The 2025 model places private providers at approximately 8% of prevalent patients but around 12% of market value because private treatment economics are higher than the public cost basis. Dhamani strengthens this opportunity by standardizing claims, eligibility and provider connectivity. The private patient share is modeled to rise gradually as employer-sponsored insurance and private healthcare utilization develop through the forecast period.

The largest structural risk is the combination of public-capacity dependence and limited transparency around private dialysis tariffs and facility-level renal revenue. Oman's latest publicly referenced national dialysis census in the sizing model is the 2022 Ministry of Health dataset, which reported 2,436 patients, 449 dialysis beds or stations and more than 334,000 sessions. Consequently, later patient and capacity estimates require disciplined extrapolation. For private providers, standardized Dhamani claims improve transparency but increase the importance of authorization, coding and reimbursement-cycle execution.

Oman has relatively high renal treatment intensity within the selected GCC peer set. The 2023 regional kidney-health assessment reported treated kidney failure prevalence of about 670 per million population in Oman, compared with 826 in Saudi Arabia, 645 in Qatar, 339.7 in Bahrain and 152 in the United Arab Emirates. Oman also reported approximately 6.6 hemodialysis centers per million population and 39.8 nephrologists per million. These indicators point to comparatively strong renal-care infrastructure despite Oman's smaller absolute population and service-market scale.

Diabetes and hypertension are the most important epidemiological demand drivers. Oman's nationally representative 2017 STEPS survey found diabetes prevalence of 15.7% among adults, while the broader STEPS analysis reported raised blood pressure in about 33% of adults. Both conditions are major pathways to progressive kidney damage and ultimately ESKD. Because these risk factors affect large population cohorts, renal-care demand is likely to remain structurally elevated even as screening, prevention, transplantation and home dialysis improve treatment efficiency.